- adj.
- 高インスリン型の、高インスリン性の、高インシュリン性の
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 乳児の持続性高インスリン血症性低血糖症の治療および合併症 treatment and complications of persistent hyperinsulinemic hypoglycemia of infancy
- 2. 幼児の持続性高インスリン血症性低血糖症の病因、臨床的特徴、および診断 pathogenesis clinical features and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy
- 3. 非インスリノーマ低血糖症候群 noninsulinoma pancreatogenous hypoglycemia syndrome
- 4. 新生児低血糖 neonatal hypoglycemia
- 5. 成人における低血糖：臨床症状、定義、および原因 hypoglycemia in adults clinical manifestations definition and causes
English Journal
- Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.
- Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D'Angelo A, Maffioli P.Author information Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; Center for the Study of Endocrine-Metabolic Pathophysiology and Clinical Research, University of Pavia, Pavia, Italy. Electronic address: giuseppe.derosa@unipv.it.AbstractAIM: Hypertension affects nearly 1 in 3 adults in the United States, and it is an important modifiable risk factor for coronary artery disease, heart failure, renal failure, and stroke. The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies.
- European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.Eur J Pharm Sci.2014 Jan 23;51:26-33. doi: 10.1016/j.ejps.2013.08.031. Epub 2013 Aug 30.
- AIM: Hypertension affects nearly 1 in 3 adults in the United States, and it is an important modifiable risk factor for coronary artery disease, heart failure, renal failure, and stroke. The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood press
- PMID 23999037
- Insulin Inhibits IL-10-Mediated Regulatory T Cell Function: Implications for Obesity.
- Han JM, Patterson SJ, Speck M, Ehses JA, Levings MK.Author information Department of Surgery, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, Canada.AbstractChronic inflammation is known to promote metabolic dysregulation in obesity and type 2 diabetes. Although the precise origin of the unchecked inflammatory response in obesity is unclear, it is known that overproduction of proinflammatory cytokines by innate immune cells affects metabolism. For example, TNF-α contributes to the inability of cells to respond to insulin and to the increase in levels of insulin. Whether this hyperinsulinemia itself is part of a feedback loop that affects the progression of chronic adipose inflammation is unknown. In this article, we show that regulatory T cells (Tregs) express the insulin receptor, and that high levels of insulin impair the ability of Tregs to suppress inflammatory responses via effects on the AKT/mTOR signaling pathway. Insulin activated AKT signaling in Tregs, leading to inhibition of both IL-10 production and the ability of Tregs to suppress the production of TNF-α by macrophages in a contact-independent manner. The effect of insulin on Treg suppression was limited to IL-10 production and it did not alter the expression of other proteins associated with Treg function, including CTLA-4, CD39, and TGF-β. In a model of diet-induced obesity, Tregs from the visceral adipose tissue of hyperinsulinemic, obese mice showed a similar specific decrease in IL-10 production, as well as a parallel increase in production of IFN-γ. These data suggest that hyperinsulinemia may contribute to the development of obesity-associated inflammation via a previously unknown effect of insulin on the IL-10-mediated function of Tregs.
- Journal of immunology (Baltimore, Md. : 1950).J Immunol.2014 Jan 15;192(2):623-9. doi: 10.4049/jimmunol.1302181. Epub 2013 Dec 9.
- Chronic inflammation is known to promote metabolic dysregulation in obesity and type 2 diabetes. Although the precise origin of the unchecked inflammatory response in obesity is unclear, it is known that overproduction of proinflammatory cytokines by innate immune cells affects metabolism. For examp
- PMID 24323581
- Novel α-MSH analog causes weight loss in obese rats and minipigs and improves insulin sensitivity.
- Fosgerau K, Raun K, Nilsson C, Dahl K, Wulff BS.Author information Novo Nordisk Diabetes Research Unit, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark.AbstractObesity is a major burden to people and to health care systems around the world. The aim of the study was to characterize the effect of a novel selective α-MSH analog on obesity and insulin sensitivity. The subchronic effects of the selective MC4-R peptide agonist MC4-NN1-0182 were investigated in diet-induced obese (DIO) rats and DIO minipigs by assessing the effects on food intake, energy consumption, and body weight. The acute effect of MC4-NN1-0182 on insulin sensitivity was assessed by a euglycemic-hyperinsulinemic clamp study in normal rats. Three weeks of treatment of DIO rats with MC4-NN1-0182 caused a decrease in food intake and a significant decrease in body weight 7±1%, P<0.05 compared with 3±1% increase with the vehicle control. In DIO minipigs, 8 weeks of treatment with MC4-NN1-0182 resulted in a body weight loss of 13.3±2.5 kg (13±3%), whereas the vehicle control group had gained 3.7±1.4 kg (4±1%). Finally, clamp studies in normal rats showed that acute treatment with MC4-NN1-0182 caused a significant increase in glucose disposal (Rd) compared with vehicle control (Rd, mg/kg per min, 17.0±0.7 vs 13.9±0.6, P<0.01). We demonstrate that treatment of DIO rats or minipigs with a selective MC4-R peptide agonist causes weight loss. Moreover, we have demonstrated weight-independent effects on insulin sensitivity. Our observations identify MC4 agonism as a viable target for the treatment of obesity and insulin resistance.
- The Journal of endocrinology.J Endocrinol.2014 Jan 8;220(2):97-107. doi: 10.1530/JOE-13-0284. Print 2014.
- Obesity is a major burden to people and to health care systems around the world. The aim of the study was to characterize the effect of a novel selective α-MSH analog on obesity and insulin sensitivity. The subchronic effects of the selective MC4-R peptide agonist MC4-NN1-0182 were investigated in
- PMID 24204009
Japanese Journal
- 臨床研究・症例報告 ジアゾキサイド中止の判断に持続血糖測定を用いた一過性高インスリン性低血糖症の1例
- 小児科臨床 69(1), 112-116, 2016-01
- NAID 40020682479
- A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin [Rapid Communication]
- Endocrine Journal advpub(0), 2016
- NAID 130005119378
- Noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS),Nesidioblastosis (膵島細胞症) (特集 低血糖症の鑑別診断)
- 内分泌・糖尿病・代謝内科 = Endocrinology, diabetology & metabolism 41(3), 205-209, 2015-09
- NAID 40020603862
Related Links
- hyperinsulinemic-euglycemic clampを施行し、stedy stateに入ったあとFDGを緩徐に静注する。血中FDG濃度をバックグランドとして補正しながら、経時的に関心領域のFDGを測定する(5)。また、 [1-13C]glucoseを使いmagnetic ...
- Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), previously called familial hyperinsulinism, congenital hyperinsulinemia, and primary islet cell hypertrophy (nesidioblastosis), is the most common cause of persistent ... ...
Related Pictures
★リンクテーブル★
| リンク元 | 「高インスリン型」「高インスリン性」「高インシュリン性」 |
| 拡張検索 | 「euglycemic hyperinsulinemic clamp法」「persistent hyperinsulinemic hypoglycemia of infancy」「euglycemic hyperinsulinemic clamp method」 |